文献速递物质与行为成瘾

胰高血糖素样肽-1受体激动剂作为阿片类使用障碍的候选治疗:从大鼠到人类

Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans.
PubMed 文献 · Biol Psychiatry · 2026-07-21

本文综述了GLP-1受体激动剂(GLP-1RA)、双重GLP-1RA+GIP受体激动剂及三重激动剂治疗阿片类使用障碍(OUD)的临床前与临床数据。临床前研究显示急性给药可减少阿片寻求行为,慢性给药高剂量出现耐受;一项小型临床试验发现利拉鲁肽使阿片渴求降低40%,另有3项试验正在进行;电子健康记录等数据提示GLP-1RA或GLP-1RA/GIP激动剂治疗与阿片过量及OUD住院减少40%相关。

要点

  • 临床前研究显示GLP-1RA急性给药减少线索、药物或应激诱发的阿片寻求行为。
  • 一项小型临床试验中利拉鲁肽使阿片渴求降低40%。
  • 电子健康记录等数据显示GLP-1RA或GLP-1RA/GIP激动剂与阿片过量及OUD住院减少40%相关。

核心结论

  • GLP-1RA、双重GLP-1RA+GIP受体激动剂及三重激动剂在临床前和初步人类数据中显示治疗OUD的前景,但需更多临床试验确认。

研究设计与样本

  • 综述临床前与临床数据,包括动物实验、小型临床试验、正在进行的临床试验及电子健康记录、TriNetX数据库和Medicare理赔数据分析。

主要发现

  • 临床前研究中,急性给予exendin-4、利拉鲁肽、司美格鲁肽、替尔泊肽及其他双重和三重激动剂可减少由药物相关线索、药物本身或应激诱发的阿片摄取和/或阿片寻求行为。
  • 慢性GLP-1RA治疗也减少阿片反应,但高剂量慢性给药出现耐受。
  • 一项小型临床试验发现利拉鲁肽治疗后阿片渴求降低40%。
  • 三项临床试验正在进行,其中两项测试司美格鲁肽、一项测试替尔泊肽作为丁丙诺啡或美沙酮的辅助治疗。
  • 电子健康记录、TriNetX数据库和Medicare理赔数据显示,因2型糖尿病和/或肥胖接受GLP-1RA或GLP-1RA/GIP激动剂治疗的患者阿片过量和OUD住院减少40%。

关键数值与推荐

  • 临床前研究:急性给予exendin-4、利拉鲁肽、司美格鲁肽、替尔泊肽及其他双重和三重激动剂减少阿片摄取和/或寻求。
  • 临床研究:利拉鲁肽使阿片渴求降低40%;电子健康记录等数据显示GLP-1RA或GLP-1RA/GIP激动剂与阿片过量及OUD住院减少40%相关。

临床怎么用

  • GLP-1RA及其双重/三重激动剂可能作为OUD的新型治疗选择,但当前证据尚不足以改变临床实践,需等待正在进行的临床试验结果。

局限性

  • 需要额外的临床试验来确认GLP-1RA治疗OUD的疗效;慢性高剂量GLP-1RA给药出现耐受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite recent progress and at least 3 medications approved for the treatment of opioid use disorder (OUD), the number of deaths due to opioid overdose remains unacceptably high. Therefore, there is a need for new treatments. To this end, glucagon-like peptide-1 receptor agonists (GLP-1RAs), dual GLP-1RA+glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (e.g., tirzepatide), and triple agonists (e.g., GLP-1RA+neuropeptideY1/Y2 receptor agonists) show promise. Here, we review preclinical and clinical data. In the preclinical studies, acute administration of exendin-4 and the longer-acting liraglutide, semaglutide, tirzepatide, and other dual and triple agonists reduced opioid taking and/or opioid seeking when elicited by exposure to drug-related cues, the drug itself, or by stress. Chronic treatment with GLP-1RAs also reduced responding for opioids, but tolerance occurred with chronic administration of higher doses of GLP-1RAs. In the human studies, 1 small clinical trial found a 40% reduction in opioid craving following treatment with the GLP-1RA liraglutide. Three other clinical trials are ongoing, with 2 testing the efficacy of semaglutide and 1 testing the efficacy of tirzepatide as adjunctive treatments to buprenorphine or methadone. Pending completion of these clinical trials, recent studies used data from electronic health records, the TriNetX database, and Medicare claims and found a 40% reduction in opioid overdose and in hospital admissions for OUD in patients treated with a GLP-1RA or a GLP-1RA/GIP agonist for type 2 diabetes and/or for obesity. Thus, while additional clinical trials are needed, these data suggest that GLP-1RAs hold promise as a novel treatment for OUD in humans.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Grigson PS, Bunce SC, Brick TR, et al. Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans. Biol Psychiatry. 2026. PMID: 42480803. doi:10.1016/j.biopsych.2026.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。